Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

IoT helps to decentralise clinical trials while providing pharmaceutical companies with a higher return on investment.

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

Antag Therapeutics has commenced a first-in-human, double-blind Phase Ia trial of the GIPR antagonist, AT-7687, intended for ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II VacSYn trial.

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...

Yingli Pharma has obtained US FDA approval for a Phase III trial of linperlisib for R/R peripheral T-cell lymphoma (PTCL).